Literature DB >> 11886240

Single oral immunization with replication deficient recombinant adenovirus elicits long-lived transgene-specific cellular and humoral immune responses.

Sally Sharpe1, Anthony Fooks, John Lee, Kevin Hayes, Christopher Clegg, Martin Cranage.   

Abstract

Oral-gastric delivery of vaccines is a preferred route of immunization and is particularly relevant to the development of vaccine-vector systems. We have investigated the ability of a replication deficient (E1-deleted) adenovirus construct (RAd68), which efficiently expresses the measles virus nucleocapsid (N) protein under the control of the strong HCMV IE promoter, to elicit antibody and cytotoxic T cell (CTL) responses in mice following intragastric administration. Measles virus N protein-specific CTL memory and serum antibody responses were analyzed in a total of 140 mice at time points 2-51 weeks after immunization either with a single dose of 10(8) pfu RAd68 or with a fivefold higher dose. Of the 20 animals analyzed in the first 4-week period following low-dose immunization, 6 mounted low-level splenic CTL responses while 13 animals had CTL in the mesenteric lymph nodes. Splenic CTL responses were largely undetectable at later times. Only 23% of low-dose-immunized mice made serum antibody responses and these were generally of low magnitude and frequently of short duration. In contrast, the majority of animals immunized orally with 5 x 10(8) pfu RAd68 mounted splenic CTL responses (70%) and/or antibody responses (89%). Notably, these responses were stronger and of greater duration than those seen following immunization at the lower dose. Gut mucosal immunization with replication deficient adenoviruses is a promising approach, not only for the development of complementary measles vaccine strategies which may be required for measles virus eradication, but also generally for vaccination against other infections.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11886240     DOI: 10.1006/viro.2001.1281

Source DB:  PubMed          Journal:  Virology        ISSN: 0042-6822            Impact factor:   3.616


  15 in total

1.  Construction and characterization of adenovirus serotype 5 packaged by serotype 3 hexon.

Authors:  Hongju Wu; Igor Dmitriev; Elena Kashentseva; Toshiro Seki; Minghui Wang; David T Curiel
Journal:  J Virol       Date:  2002-12       Impact factor: 5.103

2.  A single sublingual dose of an adenovirus-based vaccine protects against lethal Ebola challenge in mice and guinea pigs.

Authors:  Jin Huk Choi; Stephen C Schafer; Lihong Zhang; Gary P Kobinger; Terry Juelich; Alexander N Freiberg; Maria A Croyle
Journal:  Mol Pharm       Date:  2011-12-15       Impact factor: 4.939

3.  Intramuscular rather than oral administration of replication-defective adenoviral vaccine vector induces specific CD8+ T cell responses in the gut.

Authors:  S W Lin; A S Cun; K Harris-McCoy; H C Ertl
Journal:  Vaccine       Date:  2006-12-06       Impact factor: 3.641

Review 4.  Genetic medicine strategies to protect against bioterrorism.

Authors:  Julie L Boyer; Ronald G Crystal
Journal:  Trans Am Clin Climatol Assoc       Date:  2006

5.  miRNA-mediated silencing in hepatocytes can increase adaptive immune responses to adenovirus vector-delivered transgenic antigens.

Authors:  Matthias W Kron; Sigrid Espenlaub; Tatjana Engler; Reinhold Schirmbeck; Stefan Kochanek; Florian Kreppel
Journal:  Mol Ther       Date:  2011-05-10       Impact factor: 11.454

6.  An adenovirus-based vaccine with a double-stranded RNA adjuvant protects mice and ferrets against H5N1 avian influenza in oral delivery models.

Authors:  Ciaran D Scallan; Debora W Tingley; Jonathan D Lindbloom; James S Toomey; Sean N Tucker
Journal:  Clin Vaccine Immunol       Date:  2012-11-14

7.  Oral vaccination of mice with adenoviral vectors is not impaired by preexisting immunity to the vaccine carrier.

Authors:  Z Q Xiang; G P Gao; A Reyes-Sandoval; Y Li; J M Wilson; H C J Ertl
Journal:  J Virol       Date:  2003-10       Impact factor: 5.103

8.  Delivery of human immunodeficiency virus vaccine vectors to the intestine induces enhanced mucosal cellular immunity.

Authors:  Lingshu Wang; Cheng Cheng; Sung-Youl Ko; Wing-Pui Kong; Masaru Kanekiyo; David Einfeld; Richard M Schwartz; C Richter King; Jason G D Gall; Gary J Nabel
Journal:  J Virol       Date:  2009-05-06       Impact factor: 5.103

9.  Oral immunization of rhesus macaques with adenoviral HIV vaccines using enteric-coated capsules.

Authors:  George T Mercier; Pramod N Nehete; Marco F Passeri; Bharti N Nehete; Eric A Weaver; Nancy Smyth Templeton; Kimberly Schluns; Stephanie S Buchl; K Jagannadha Sastry; Michael A Barry
Journal:  Vaccine       Date:  2007-11-05       Impact factor: 3.641

10.  Identification of sites in adenovirus hexon for foreign peptide incorporation.

Authors:  Hongju Wu; Tie Han; Natalya Belousova; Victor Krasnykh; Elena Kashentseva; Igor Dmitriev; Manjula Kataram; Parameshwar J Mahasreshti; David T Curiel
Journal:  J Virol       Date:  2005-03       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.